Ketone bodies are endogenous metabolites that can fuel the heart and circulating ketone bodies are increased in patients with chronic heart failure (HF). However, little is known about ketone body concentrations in the setting of acute HF.
SN Voorrips; BD Westenbrink et al. performed a longitudinal analysis of ketone body concentrations in the EMPA-response-AHF which randomized patients with acute HF to empagliflozin or placebo. A significant rise and fall in circulating ketone bodies was discovered in patients with acute decompensated HF. Treatment with empagliflozin did not affect ketone body concentrations in this setting. These data suggest that ketone body metabolism is activated during episodes of acute HF.